Last 48 quarters of trend data · Healthcare · Immunology Biotech
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -7.32 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 85.09 | 132.70 | 115.88 | 60.50 | 71.28 | 17.66 | 24.49 | 32.17 | 6.42 | 4.72 | 7.09 | 9.19 | 1.06 | 13.06 | 97.98 | 53.50 | 33.87 | 13.80 | 150.72 | 182.22 | 148.28 |
| — | +651.6% | +373.2% | +88.0% | +1011.1% | +273.9% | +245.5% | +250.2% | +505.9% | -63.9% | -92.8% | -82.8% | -96.9% | -5.3% | -35.0% | -70.6% | -77.2% | -91.7% | +16.0% | +2.1% | +240.5% | |
| P/B Ratio | 4.64 | 4.71 | 6.06 | 3.36 | 3.58 | 1.94 | 1.32 | 1.30 | 1.52 | 0.63 | 0.59 | 0.62 | 0.47 | 3.10 | 4.07 | 3.06 | 5.31 | 4.77 | 3.91 | 5.88 | 4.51 |
| — | +142.9% | +358.7% | +158.7% | +135.7% | +207.6% | +125.5% | +109.4% | +221.0% | -79.7% | -85.6% | -79.7% | -91.1% | -35.0% | +4.3% | -47.9% | +17.8% | -6.2% | -3.6% | -48.0% | -38.3% | |
| P/FCF | — | — | — | — | — | — | — | — | — | 0.93 | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 73.3% | 87.2% | 85.8% | 80.2% | 162.0% | 83.7% | -4.1% | 65.2% | -1.0% | 44.6% | 31.0% | 23.3% | 63.4% | 11.7% | 14.8% | 26.1% | 80.5% | 56.8% | 30.1% | 20.5% | 23.5% |
| — | +4.2% | +2189.1% | +23.0% | +16680.5% | +87.7% | -113.3% | +180.3% | -101.5% | +279.7% | +109.1% | -10.7% | -21.2% | -79.3% | -50.8% | +27.1% | +243.1% | +68.2% | -2.1% | -36.6% | +26.0% | |
| Operating Margin | -975.9% | -1441.2% | -1487.9% | -1111.8% | -1755.5% | -519.8% | -1035.9% | -1242.9% | -1082.1% | -240.9% | -464.7% | -789.4% | -23.0% | -340.2% | -1702.2% | -1183.5% | -375.1% | -109.8% | -1374.0% | -1301.2% | -1525.2% |
| — | -177.2% | -43.6% | +10.5% | -62.2% | -115.8% | -122.9% | -57.4% | -4598.1% | +29.2% | +72.7% | +33.3% | +93.9% | -209.9% | -23.9% | +9.1% | +75.4% | +91.0% | -39.2% | +18.9% | -77.7% | |
| Net Margin | -829.6% | -1249.8% | -1320.1% | -993.2% | -1528.6% | -443.0% | -868.3% | -1036.8% | -1048.2% | -174.6% | -397.2% | -706.5% | -8.5% | -315.2% | -1582.1% | -1113.9% | -356.4% | -104.9% | -1343.7% | -1293.1% | -1519.3% |
| — | -182.1% | -52.0% | +4.2% | -45.8% | -153.8% | -118.6% | -46.8% | -12252.3% | +44.6% | +74.9% | +36.6% | +97.6% | -200.5% | -17.7% | +13.9% | +76.5% | +91.8% | -35.0% | +20.1% | -82.2% |
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -50.2% | -12.7% | -16.0% | -16.1% | -17.7% | -11.6% | -11.2% | -10.1% | -67.6% | -5.7% | -8.0% | -11.3% | -1.0% | -17.4% | -16.6% | -15.0% | -13.2% | -8.8% | -9.9% | -10.0% | -11.0% |
| — | -9.5% | -43.3% | -59.6% | +73.8% | -101.9% | -40.5% | +11.1% | -7005.6% | +67.0% | +52.0% | +24.7% | +92.8% | -98.8% | -68.0% | -51.1% | -20.2% | +6.7% | +5.9% | +74.0% | +67.2% | |
| ROA | -34.1% | -9.4% | -11.4% | -11.0% | -11.8% | -8.0% | -8.0% | -7.2% | -47.9% | -4.4% | -6.6% | -9.1% | -0.7% | -12.9% | -12.7% | -11.6% | -10.6% | -7.3% | -8.1% | -7.9% | -8.9% |
| — | -16.7% | -42.6% | -53.1% | +75.4% | -81.4% | -21.5% | +20.9% | -6585.7% | +65.7% | +48.4% | +21.6% | +93.2% | -76.2% | -56.1% | -47.8% | -19.4% | +4.6% | -0.7% | +68.2% | +52.0% | |
| ROIC | -53.0% | -12.7% | -16.3% | -16.5% | -18.7% | -12.5% | -12.3% | -11.0% | -69.2% | -7.9% | -8.6% | -12.5% | -2.6% | -17.8% | -16.9% | -15.7% | -14.0% | -9.6% | -10.1% | -9.0% | -10.3% |
| — | -1.7% | -33.2% | -50.0% | +73.0% | -58.4% | -42.3% | +12.1% | -2580.9% | +55.6% | +49.1% | +20.5% | +81.5% | -85.6% | -68.2% | -74.6% | -36.1% | +7.1% | +18.0% | +75.8% | +72.1% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.02 | — | — | 0.01 | 0.02 | 0.02 | 0.02 | 0.02 | — | 0.02 | 0.02 | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| — | — | — | -19.9% | — | -10.3% | -14.7% | -29.5% | — | +950.0% | +725.9% | +617.4% | -21.7% | -43.1% | -18.9% | -14.2% | -1.5% | +12.8% | -93.5% | -96.1% | -98.8% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 5.28 | 5.09 | 3.46 | 4.03 | 5.28 | 3.92 | 3.88 | 5.06 | 3.99 | 7.03 | 7.50 | 6.74 | 4.16 | 4.50 | 5.82 | 10.10 | 10.55 | 12.97 | 15.99 | 11.41 | 8.94 |
| — | +29.6% | -10.8% | -20.4% | +32.6% | -44.2% | -48.2% | -25.0% | -4.2% | +56.1% | +28.8% | -33.3% | -60.6% | -65.3% | -63.6% | -11.5% | +18.0% | +12.4% | -1.1% | +23.1% | +131.3% | |
| Quick Ratio | 5.28 | 5.09 | 3.46 | 4.03 | 5.28 | 3.92 | 3.88 | 5.06 | 3.99 | 7.03 | 7.50 | 6.74 | 4.16 | 4.50 | 5.82 | 10.10 | 10.55 | 12.97 | 15.99 | 11.41 | 8.94 |
| — | +29.6% | -10.8% | -20.4% | +32.6% | -44.2% | -48.2% | -25.0% | -4.2% | +56.1% | +28.8% | -33.3% | -60.6% | -65.3% | -63.6% | -11.5% | +18.0% | +12.4% | -1.1% | +23.1% | +131.3% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -8.49 | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ACRS stock.
Aclaris Therapeutics, Inc.'s current P/E is -7.3x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Aclaris Therapeutics, Inc.'s current operating margin is -975.9%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Aclaris Therapeutics, Inc.'s business trajectory between earnings reports.